Anemia
Pipeline by Development Stage
Drug Modality Breakdown
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 9.0yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.7yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 4.2yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.4yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 1.2yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
On Market (4)
Approved therapies currently available
Competitive Landscape
53 companies ranked by most advanced pipeline stage
+23 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 47 trials with date data
Clinical Trials (50)
Total enrollment: 10,394 patients across 50 trials
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
A Study of NeoRecormon in Patients With Chronic Kidney Disease.
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
Preoperative Monoferric for Abdominal Surgery
Management of Preoperative Anaemia in Surgical Oncology
Iron Replacement in Oesophagogastric Neoplasia
A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia
A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis
A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients
A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
Dynepo Long-Term Safety Study
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
STAAR-3 Clinical Study
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
STAAR-1 Clinical Study
STAAR-2 Clinical Study
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Maintenance Treatment of Renal Anemia in Dialysis Subjects
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
Related Jobs in Hematology
Associate Director, Clinical Scientist, Genetics Medicine
MEDICAL MANAGER JUNIOR HEMATOLOGIE H/F
Patient Value Partner Hematology
Manager, Biostatistics - General Medicine
Internship in Innovation & Sustainability - For students in the field of Digital Health, Health Informatics, Biomedical Engineering, Healthcare IT, or Computer Science
Director Medical Communications
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.